GlassScriptPhysician profile
Jonathan D Parker
NPI 1710272265
$213,658.30
in general payments reported to CMS, 2019-2025
34 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $36K · 2021: $55K · 2022: $29K · 2023: $8,978 · 2024: $32K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Consulting Fee: $5,719 · Travel and Lodging: $3,614 · Food and Beverage: $2,916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,493.39 |
| Consulting Fee | $5,718.75 |
| Travel and Lodging | $3,613.50 |
| Food and Beverage | $2,915.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $211,182.08 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $383.44 | 2021-2025 | |
| Horizon Therapeutics Plc | $215.61 | 2020-2022 | |
| Lilly USA, LLC | $210.96 | 2019-2024 | Mounjaro |
| Glaxosmithkline, LLC. | $170.01 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $166.95 | 2019-2025 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.33 | 2019-2022 | |
| Corcept Therapeutics | $154.02 | 2025 | Korlym |
| Pfizer INC. | $138.56 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $130.37 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.84 | 2019-2025 | Trintellix |
| Astellas Pharma US INC | $57.73 | 2020-2024 | Veozah |
| Amgen INC. | $53.20 | 2019-2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $52.75 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Supernus Pharmaceuticals, INC. | $47.93 | 2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $44.78 | 2023-2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $42.86 | 2021-2025 | Xyosted |
| Rhythm Pharmaceuticals, INC. | $38.40 | 2022-2023 | Imcivree |
| Amarin Pharma, INC. | $38.01 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $37.86 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $23.99 | 2019 | |
| Allergan, INC. | $23.80 | 2020 | |
| Bausch Health US, LLC | $20.16 | 2025 | Wellbutrin, Aplenzin |
| Medtronic, INC. | $18.25 | 2021 | |
| Abbott Laboratories | $16.89 | 2021 | |
| Inspire Medical Systems, INC. | $16.72 | 2025 | Inspire |
| Daiichi Sankyo INC. | $15.80 | 2020 | |
| Tactile Systems Technology INC | $15.77 | 2025 | Flexitouch Plus, Nimbl |
| Esperion Therapeutics, INC. | $15.52 | 2021 | |
| Ironwood Pharmaceuticals, INC | $15.20 | 2020 | |
| Philips North America LLC | $15.14 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Celgene Corporation | $13.95 | 2019 | |
| Tolmar, INC. | $13.93 | 2024 | |
| Phathom Pharmaceuticals, INC. | $10.49 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.